Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Flagstar Bank NA (FLG) vs Inovio Pharmaceuticals Inc (INO) Price & Performance

Flagstar Bank NATrade
Inovio Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Flagstar Bank NA vs Inovio Pharmaceuticals Inc — how do they compare? Flagstar Bank NA trades at $14.2 (market cap $5.89B), while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: Flagstar Bank NA is far larger — about 75× Inovio Pharmaceuticals Inc's market cap, and Flagstar Bank NA pays a 0.28% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

FLGINO
Market Cap
$5.89B$78.55M
Sector
FinancialsHealth
52-Week High
$15.36$2.87
52-Week Low
$10.72$0.66
Dividend Yield
0.28%
Enterprise Value
$49.56M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Flagstar Bank NA

FLG trades at $14.21, up 1.43% today, with a bullish technical signal from moving averages. The stock shows a low P/B of 0.77 but a high P/E of 473, reflecting recent profitability after a 2025 net loss. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and declared dividends, signaling financial strength. Analyst consensus is a Buy with a $16.85 price target, indicating potential upside from current levels.

The outlook is cautiously optimistic, supported by analyst bullishness and strategic initiatives like technology transformation. Key risks include earnings volatility, competitive pressures in banking, and macroeconomic sensitivity. The stock presents a value opportunity based on price-to-book, but sustained earnings growth is crucial for justifying the elevated P/E ratio.

Inovio Pharmaceuticals Inc

INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.

The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Flagstar Bank NA

Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.

Read more on FLG

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO